After a red-hot start, biotech IPOs are now underperforming the broader market.
Orexigen Therapeutics is the best-performing obesity drug stock of 2013, topping rivals Vivus and Arena Pharma.
Optina's 505(b)(2) filing strategy appears to be running into trouble with the FDA, according to Ampio's SEC filings.
Contrave will be resubmitted for FDA approval "within a few weeks," Orexigen said.
Biogen Idec and Gilead Sciences are helping the biotech sector recover from a sloppy fourth quarter performance.
European regulators decide Tecfidera is a "new active substance," clearing way for Biogen to begin selling the multiple sclerosis drug.
European regulators place new patient restrictions on Iclusig but Ariad can continue to sell the drug.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.
Amicus loses ground to rivals Sanofi and BioMarin in the race to develop drugs for rare, orphan diseases.